Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care

REFERENCES

• Center to Advance Palliative Care. National Palliative Care Registry. Available at: registry.capc.org. 2014. Accessed January 2, 2015.
   Google Scholar
• Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care. 2004;13:424–433.
   PubMed Web of Science ®Google Scholar
• Yennurajalingam S, Braiteh F, Bruera E. Pain and terminal delirium research in the elderly. Clin Geriatr Med. 2005;21:93–119, viii.
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Appropriate use of opioids for persistent non-cancer pain. Lancet. 2004;364:739–740.
   PubMed Web of Science ®Google Scholar
• Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–763.
   PubMed Web of Science ®Google Scholar
• Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manage. 2014;10:207–215.
   PubMedGoogle Scholar
• Schrijvers D. Pain control in cancer: recent findings and trends. Ann Oncol. 2007;18(Suppl 9): ix, 37–42.
   Google Scholar
• Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20:1420–1433.
   PubMed Web of Science ®Google Scholar
• Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59:850–856.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84:602–612.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–134.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–281.
   PubMed Web of Science ®Google Scholar
• Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology. 1991;75:223–229.
   PubMed Web of Science ®Google Scholar
• Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs. 2010;70:57–72.
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123–130.
   PubMed Web of Science ®Google Scholar
• Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage. 2008;35:563–567.
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;(1):CD004311.
   Google Scholar
• Laverty D. Actiq: an effective oral treatment for cancer-related breakthrough pain. Br J Community Nurs. 2007;12: 311, 313–316.
   Google Scholar
• Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care. 2005;22:228–232.
   PubMedGoogle Scholar
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181–190.
   PubMed Web of Science ®Google Scholar
• Kestenbaum MG, Vilches AO, Messersmith S, et al. Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med. 2014;15:1129–1153.
   PubMed Web of Science ®Google Scholar
• Jackson LD, Little J, Kung E, Williams EM, Siemiatkowska K, Plowman S. Safe medication swallowing in dysphagia: a collaborative improvement project. Healthc Q. 2008;11(3 Spec. No.):110–116.
   PubMedGoogle Scholar
• Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695–1700.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. Intranasal transmucosal fentanyl pectin for breakthrough cancer pain in radiation-induced oropharyngeal mucositis (CP073). Available at: http://clinicaltrials.gov/ct2/show/NCT02050503?term=nct02050503&rank=1 Accessed November 14, 2014.
   Google Scholar
• Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, Lennernas H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59: 249–253.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Abstral prescribing information. Available at: http://www.abstral.com/sites/default/files/ABSTRAL-Full-PI.pdf. Accessed January 8, 2015.
   Google Scholar
• Nalamachu S. An evaluation of total disintegration time for three different doses of sublingual fentanyl tablets in patients with breakthrough pain. Pain Ther. 2013;2:121–128.
   PubMedGoogle Scholar
• Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–2885.
   PubMed Web of Science ®Google Scholar
• Shimoyama N, Gomyo I, Katakami N, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. Int J Clin Oncol. 2015;20:198–206.
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011;27: 519–530.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Subsys prescribing information. Available at: http://www.accessdata. fda.gov/drugsatfda_docs/label/2012/202788s000lbl.pdf. Accessed December 12, 2014.
   Google Scholar
• Parikh N, Goskonda V, Chavan A, Dillaha L. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study. Clin Drug Invest. 2013;33:391–400.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41:661–680.
   PubMed Web of Science ®Google Scholar
• Parikh N, Goskonda V, Chavan A, Dillaha L. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. Clin Ther. 2013;35:236–243.
   PubMed Web of Science ®Google Scholar
• Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012;28:859–870.
   PubMed Web of Science ®Google Scholar
• Rauck R, Parikh N, Dillaha L, Barker J, Stearns L. Patient satisfaction with fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. Pain Pract. 2015; 15:554–563.
   PubMedGoogle Scholar
• Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med. 2003;17:219–221.
   PubMed Web of Science ®Google Scholar
• Instanyl. Instanyl summary of product characteristics. Available at: http://www.instanyl.com/∼/media/Products/instanyl_com/Protected/Files/Instanyl_SmPC-Booklet_WEB_250110.pdf. Accessed October 10, 2014.
   Google Scholar
• Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30:469–481.
   PubMed Web of Science ®Google Scholar
• Foster D, Upton R, Christrup L, Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008;42:1380–1387.
   PubMed Web of Science ®Google Scholar
• Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manage. 2010;6:17–26.
   PubMedGoogle Scholar
• Nave R, Connolly SM, Popper L, Lahu G, Schmitt H. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. Int J Clin Pharmacol Ther. 2012;50:751–759.
   PubMed Web of Science ®Google Scholar
• Nave R, Schmitt H, Popper L. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects. Drug Deliv. 2013;20:216–223.
   PubMed Web of Science ®Google Scholar
• Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. 2010;48:138–145.
   PubMed Web of Science ®Google Scholar
• Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177–1191.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Prestia G, Adile C, Casuccio A. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. J Pain. 2014;15:602–607.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805–2815.
   PubMed Web of Science ®Google Scholar
• Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. 2000;20:253–258.
   PubMed Web of Science ®Google Scholar
• Kongsgaard UE, Eeg M, Greisen H. The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study. Support Care Cancer. 2014;22:1655–1662.
   PubMed Web of Science ®Google Scholar
• Bulloch MN, Hutchison AM. Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain. Expert Rev Clin Pharmacol. 2013;6:9–22.
   PubMed Web of Science ®Google Scholar
• Lazanda. Lazanda prescribing information. Available at: http://www.lazanda.com/sites/all/themes/lazanda/pdfs/Lazan da_Prescribing_Information.pdf. Accessed October 10, 2014.
   Google Scholar
• Perelman M, Fisher AN, Smith A, Knight A. Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. Int J Clin Pharmacol Ther. 2013;51:349–356.
   PubMed Web of Science ®Google Scholar
• Perelman M, Knight A. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. Int J Clin Pharmacol Ther. 2013;51:942–947.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617–624.
   PubMed Web of Science ®Google Scholar
• Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol. 2010;8:184–190.
   PubMedGoogle Scholar
• Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J pain and symptom management. 2011;41:358–366.
   PubMed Web of Science ®Google Scholar
• Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224–231.
   PubMedGoogle Scholar
• Radbruch L, Torres LM, Ellershaw JE, et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer. 2012;20:565–573.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Fentora prescribing information. Available at: http://www.fentora.com/pdfs/pdf100_prescribing_info.pdf. Accessed January 8, 2015.
   Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J Clin Pharmacol. 2007;47:56–63.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 2007;47:343–350.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Tracewell W, Xie F. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 μg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study. Clin Drug Invest. 2010;30:365–373.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Invest. 2007;27:605–611.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Messina J, Xie F, Portenoy RK. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med. 2010;11:1313–1327.
   PubMed Web of Science ®Google Scholar
• Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer. 2009;115:2571–2579.
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Messina J, Xie F, Slatkin NE. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract. 2010;10:287–293.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805–811.
   PubMed Web of Science ®Google Scholar
• Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327–334.
   PubMedGoogle Scholar
• Webster LR, Slevin KA, Narayana A, Earl CQ, Yang R. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013;14:1332–1345.
   PubMed Web of Science ®Google Scholar
• Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112:693–702.
   PubMed Web of Science ®Google Scholar
• Newswire P. ONSOLIS relaunch postponed pending product modification. Available at: http://www.prnewswire.com/news-releases/onsolis-relaunch-postponed-pending-product-modification-142297545.html. Published 2012. Accessed March 9, 2015.
   Google Scholar
• Food and Drug Administration. Onsolis prescribing information. Available at: http://www.accessdata.fda. gov/drugsatfda_docs/label/2009/022266s000lbl.pdf. Accessed January 13, 2015.
   Google Scholar
• Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11:1017–1023.
   PubMed Web of Science ®Google Scholar
• Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Invest. 2009;29:647–654.
   PubMed Web of Science ®Google Scholar
• Davies A, Finn A, Tagarro I. Intra- and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis. Clin Drug Invest. 2011;31:317–324.
   PubMed Web of Science ®Google Scholar
• Finn AL, Hill WC, Tagarro I, Gever LN. Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis. J Pain Res. 2011;4:245–251.
   PubMedGoogle Scholar
• Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308–1314.
   PubMed Web of Science ®Google Scholar
• Thronaes M, Kaasa S, Dale O. A pilot study of nasal fentanyl for patient controlled treatment of cancer pain. J Opioid Manage. 2014;10:21–28.
   PubMedGoogle Scholar
• Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manage. 2010;6:319–328.
   PubMedGoogle Scholar
• Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage. 2010;40:747–760.
   PubMed Web of Science ®Google Scholar
• Jandhyala R, Fullarton J. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. BMJ Support Palliat Care. 2012;2:156–162.
   PubMedGoogle Scholar
• Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46:573–580.
   PubMed Web of Science ®Google Scholar
• Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing. conversion dilemmas. J Pain Symptom Manage. 2001;21:397–406.
   PubMed Web of Science ®Google Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–465.
   PubMed Web of Science ®Google Scholar
• ExpressScripts. Transmucosal Immediate Release Fentanyl (TIRF) Products. Express Scripts. Medco. Available at: http://www.hmsa.com/PORTAL/PROVIDER/Fentanyl_Trans mucosal_Summary_060112.pdf. Accessed November 20, 2014.
   Google Scholar
• North Carolina State Health Plan. North Carolina State Health Plan. Available at: http://www.shpnc.org/library/pdf/pharmacy/fentanyl.pdf. Accessed November 20, 2014.
   Google Scholar
• RegenceRx. Therapeutic class review. Available at: http://www.regencerx.com/docs/physicianRx/pain-short-acting-0612.pdf. Accessed November 20, 2014.
   Google Scholar
• Rocky Mountain Health Plans. Uniform Pharmacy Prior Authorization Form. Available at: http://www.rmhp.org/docs/default-source/provider/lazanda_%28fentanyl_-nasal_spray%29. pdf?sfvrsn = 6. Accessed November 20, 2014.
   Google Scholar
• Obermeyer Z, Makar M, Abujaber S, Dominici F, Block S, Cutler DM. Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer. JAMA. 2014;312:1888–1896.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Turriziani A, Oradei M. Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. Expert Rev Pharmacoecon Outcomes Res. 2014;14:459–464.
   PubMed Web of Science ®Google Scholar
• Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013;27:167–175.
   PubMedGoogle Scholar